,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2014-01-15,"St. Jude Medical Inc. ( STJ ) released its preliminary results for the fourth quarter of 2013, where revenues surpassed the Zacks Consensus Estimate as well as the year-ago level.",0.8414548635482788,0.01566356234252453,0.1428815722465515,positive,0.8257912993431091
1,2014-01-15,"Shares of the company hit a new 52-week high of $68.39 soon after the announcement on Jan 13 and closed at $66.15 yesterday, up 0.2% since the release of the preliminary results.",0.9398794174194336,0.029036154970526695,0.031084422022104263,positive,0.9108432531356812
2,2014-01-15,"STJ expects revenues of $1,422 million for the fourth quarter of 2013, up 4% from $1,372 million earned in the fourth quarter of 2012.",0.9597044587135315,0.021367838606238365,0.018927669152617455,positive,0.9383366107940674
3,2014-01-15,"On a currency neutral basis, revenues grew 6% from the fourth quarter of 2012.",0.9514591097831726,0.01688944734632969,0.03165139630436897,positive,0.9345696568489075
4,2014-01-15,"St. Jude's expected revenues for the quarter exceeded the Zacks Consensus Estimate of $1,379 million but falls within its previous guidance of $1,315 to $1,395 million.",0.20305843651294708,0.7388338446617126,0.058107730001211166,negative,-0.5357754230499268
5,2014-01-15,"In the Cardiac Rhythm Management (CRM) division, STJ expects revenues of $705 million, up 3% from the year-ago level.",0.960198163986206,0.019759168848395348,0.020042648538947105,positive,0.940438985824585
6,2014-01-15,"Excluding the currency impact, CRM sales are expected to increase by 5%.",0.958063006401062,0.01674383133649826,0.02519317902624607,positive,0.9413191676139832
7,2014-01-15,"Of the total revenue in the CRM division, implantable cardiac defibrillator (ICD) revenues are expected to go up by 5% (both on a reported and constant currency basis) to $442 million in the quarter.",0.9532073736190796,0.016887634992599487,0.029905028641223907,positive,0.9363197088241577
8,2014-01-15,"Meanwhile, pacemaker sales are expected to move up by 1% (4% on a constant currency basis) to $263 million.",0.9550687074661255,0.019794398918747902,0.025136958807706833,positive,0.9352743029594421
9,2014-01-15,"In the Atrial Fibrillation division, revenues are expected to increase by 5% (8% on a constant currency basis) to $252 million.",0.9544880390167236,0.01596900261938572,0.02954292669892311,positive,0.9385190606117249
10,2014-01-15,"In the cardiovascular division, revenues are expected to go up 4% (7% on a constant currency basis) to $350 million for the fourth quarter of 2013.",0.9514040946960449,0.017210828140378,0.03138504922389984,positive,0.9341932535171509
11,2014-01-15,"Of the total revenue in the cardiovascular division, vascular products revenues are expected to dip 2% to $183 million, but increase 2% on a constant currency basis over the fourth quarter of 2012.",0.050448544323444366,0.9183800220489502,0.03117145225405693,negative,-0.8679314851760864
12,2014-01-15,"Meanwhile, structural heart product revenues are expected to go up 10% (12% on a constant currency basis) to $167 million.",0.9548108577728271,0.018376551568508148,0.026812700554728508,positive,0.9364343285560608
13,2014-01-15,"In the Neuromodulation division, revenues are expected to rise 2% to $115 million, both on a reported and constant currency basis.",0.9539146423339844,0.016222888603806496,0.02986251562833786,positive,0.9376917481422424
14,2014-01-15,"For the fourth quarter of 2013, St. Jude anticipates earnings per share in the range of 97 cents to 99 cents, an increase of 2 cents over both the top and bottom ends of its previously issued guidance range.",0.9507898688316345,0.018021509051322937,0.031188536435365677,positive,0.9327683448791504
15,2014-01-15,The Zacks Consensus Estimate is at the bottom end of its revised guided range.,0.055880509316921234,0.3611544370651245,0.582965075969696,neutral,-0.3052739202976227
16,2014-01-15,"Adjusted earnings per share exclude after-tax charges of 55 cents per share, primarily related to ongoing restructuring actions and certain other corporate charges.",0.018184807151556015,0.0880957767367363,0.8937194347381592,neutral,-0.06991097331047058
17,2014-01-15,"Currently, St. Jude carries a Zacks Rank #3 (Hold).",0.03662055358290672,0.021883057430386543,0.9414964318275452,neutral,0.01473749615252018
18,2014-01-15,The company is expected to release its complete fourth quarter and full year results on Jan 22.,0.035422272980213165,0.005862264893949032,0.9587154984474182,neutral,0.02956000715494156
19,2014-01-15,"Some better-ranked stocks in the medical products industry include Cardiovascular Systems Inc. ( CSII ), Mead Johnson Nutrition Company ( MJN ), and Advaxis, Inc. ( ADXS ).",0.6417674422264099,0.025896066799759865,0.33233651518821716,positive,0.6158713698387146
20,2014-01-15,"Cardiovascular Systems and Mead Johnson Nutrition carry a Zacks Rank #1 (Strong Buy), while Advaxis has a Zacks Rank #2 (Buy).",0.44376352429389954,0.022304987534880638,0.5339314937591553,neutral,0.42145854234695435
21,2014-01-15,To read this article on Zacks.com click here.,0.01796119473874569,0.019245078787207603,0.9627937078475952,neutral,-0.001283884048461914
22,2014-01-15,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
